WuXi PharmaTech and DNAnexus Form Genomic Cloud Partnership; WuXi Invests $15 Million

WuXi PharmaTech, the China-US CRO/CMO, deepened its commitment to genomics by making a $15 million investment in DNAnexus, a Boston company with a cloud-based genomic informatics and data management platform. WuXi and DNAnexus will partner to allow web-based access to the genomic services of another WuXi subsidiary, WuXi NextCode Genomics, providing NextCode's proprietary database infrastructure along with its clinical and research tools on the DNAnexus cloud. The partnership helps WuXi accomplish one of its major goals: to create an open access platform that offers all of its CRO services to researchers anywhere in the world. More details.... Stock Symbol: (NYSE: WX) Share this with colleagues: // //